The purpose of this Web site is to assist physicians and healthcare professionals with information and resources about CTCL and its treatment.
You are encouraged to report negative side effects of prescription drugs to the US Food and Drug Administration (FDA). Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
A review of CTCL, its symptoms, diagnosis, and treatment
A detailed description of the procedure
Learn how to answer common questions and educate patients on what to expect
Downloadable resources for device operators
An overview of how our patient assistance programs may be able to help
Learn more about IIS and Educational Grant opportunities.
Specially designed for medical professionals to use in their practice.
Sherry's Experience
The Caregiver's Perspective
The Long Journey
About THERAKOS™ Photopheresis Treatment
How THERAKOS™ Photopheresis Works
See top Opinion Leaders address FAQs about THERAKOS™ Photopheresis
Indications
Methoxsalen Sterile Solution is indicated for extracorporeal administration with the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis System in the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) that is unresponsive to other forms of treatment.
Methoxsalen should be used only by physicians who have special training in the THERAKOS™ UVAR XTS® or THERAKOS™ CELLEX® Photopheresis Systems. Methoxsalen is contraindicated in patients exhibiting idiosyncratic reactions to psoralen compounds, patients with a specific history of a light sensitive disease, or patients with aphakia.
THERAKOS™ Photopheresis is not appropriate for patients who cannot tolerate extracorporeal volume loss or shifts, or patients with coagulation disorders. See Important Safety Information for additional details.
